- Home
- BNZI vs BCDA Comparison
BNZI vs BCDA Comparison
Compare BNZI & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNZI
- BCDA
- Stock Information
- Founded
- BNZI 2016
- BCDA N/A
- Country
- BNZI United States
- BCDA United States
- Employees
- BNZI N/A
- BCDA N/A
- Industry
- BNZI
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- BNZI
- BCDA Health Care
- Exchange
- BNZI Nasdaq
- BCDA Nasdaq
- Market Cap
- BNZI 12.3M
- BCDA 10.1M
- IPO Year
- BNZI N/A
- BCDA N/A
- Fundamental
- Price
- BNZI $3.26
- BCDA $1.90
- Analyst Decision
- BNZI Strong Buy
- BCDA Strong Buy
- Analyst Count
- BNZI 1
- BCDA 1
- Target Price
- BNZI $240.00
- BCDA $25.00
- AVG Volume (30 Days)
- BNZI 404.3K
- BCDA 651.7K
- Earning Date
- BNZI 08-14-2025
- BCDA 08-11-2025
- Dividend Yield
- BNZI N/A
- BCDA N/A
- EPS Growth
- BNZI N/A
- BCDA N/A
- EPS
- BNZI N/A
- BCDA N/A
- Revenue
- BNZI $9,021,543.00
- BCDA N/A
- Revenue This Year
- BNZI $337.60
- BCDA N/A
- Revenue Next Year
- BNZI $91.81
- BCDA N/A
- P/E Ratio
- BNZI N/A
- BCDA N/A
- Revenue Growth
- BNZI 107.94
- BCDA N/A
- 52 Week Low
- BNZI $2.65
- BCDA $1.63
- 52 Week High
- BNZI $112.00
- BCDA $4.66
- Technical
- Relative Strength Index (RSI)
- BNZI 44.71
- BCDA 42.74
- Support Level
- BNZI $3.60
- BCDA $1.65
- Resistance Level
- BNZI $4.23
- BCDA $1.95
- Average True Range (ATR)
- BNZI 0.49
- BCDA 0.12
- MACD
- BNZI 0.17
- BCDA -0.00
- Stochastic Oscillator
- BNZI 55.17
- BCDA 37.29
About BNZI Banzai International Inc.
Banzai International Inc is a marketing technology (MarTech) company that produces data-driven marketing and sales solutions for businesses of all sizes. Its mission is to help its customers accomplish their mission by enabling marketing, sales and customer engagement outcomes. The company has two reportable operating segments, Banzai Operating and OpenReel. The company's segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions for business of all size. it derives maximum revenue from Banzai Operating segment. Geographically, it operates in Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).